Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrotic Lipid-lowering drug that effectively reduces cholesterol and triglyceride concentrations.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 46.00 | |
5 mg | In stock | $ 109.00 | |
10 mg | In stock | $ 189.00 | |
25 mg | In stock | $ 319.00 | |
50 mg | In stock | $ 475.00 | |
100 mg | In stock | $ 682.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 86.00 |
Description | Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrotic lipid-lowering drug that effectively reduces cholesterol and triglyceride concentrations. |
In vitro | The administration of 10 μM Cetaben for 24 hours induces severe micromorphological and ultrastructural changes in HepG2 and MH1C1 cells. After the administration of 10 μM Cetaben for 24 hours, cells were characterized by a striking heterogeneity of the peroxisomal population with the occurrence of dumbbell-shaped and cup-shaped peroxisomal profiles in MH1C1cells. After administration with 100 μM cetaben, cells contained several Golgi regions, most of them disintegrated into vesicles[2]. |
In vivo | Administration of 50-100 mg/kg Cetaben for over 10 days shows an obvious rise in the activities of peroxisomal enzymes in both the liver and kidney. However, the maximal effect is observed at 250 mg/kg[1]. |
Molecular Weight | 361.56 |
Formula | C23H39NO2 |
CAS No. | 55986-43-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 20 mg/mL (55.32 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cetaben 55986-43-1 Others proliferator peroxisome cholesterol exceptional triglycerides Inhibitor inhibit non-fibrate hypolipidemic PPARα drug inhibitor